TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00112918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered as an intravenous infusion over 30 - 90 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered as an intravenous infusion over 30 - 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: Administered as either a bolus injection or continuous intravenous infusion over 22 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Administered as either a bolus injection or continuous intravenous infusion over 22 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an intravenous infusion over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an intravenous infusion over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an intravenous infusion over 2 hours.
Study: NCT02421302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: This is ready-to-use-therapeutic-food

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: This is ready-to-use-therapeutic-food
Study: NCT02853526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
Study: NCT03096561

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood draw from three different vessels
Description: Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
Study: NCT01737411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cesa/vasa
Description: surgical repair of USL
Study: NCT01964989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Description: 1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Description: 1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Study: NCT02517736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib at a dose of 800 mg / day
Study: NCT03100656

Intervention type: OTHER
Group type: OTHER
Intervention: A breakfast sandwich
Description: A meat-based breakfast sandwich

Intervention type: OTHER
Group type: OTHER
Intervention: A breakfast sandwich
Description: A meat-based breakfast sandwich

Intervention type: OTHER
Group type: OTHER
Intervention: A breakfast sandwich
Description: A meat-based breakfast sandwich
Study: NCT03176121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
Study: NCT00447525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REVAXIS®

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT-Polio®
Study: NCT02061813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abametapir Lotion 0.74% w/w
Description: applied 0.2 mL topically under occlusive condition

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Lauryl Sulfate
Description: Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.

Intervention type: DRUG
Group type: OTHER
Intervention: Saline 0.9%
Description: A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03934008

Intervention type: OTHER
Intervention: MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)
Description: The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
Study: NCT03952572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750mg/m² ivgtt on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m² ivgtt on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: 40mg/m² ivgtt on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m²(Maximum 2 mg) ivgtt on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m²(Maximum 2 mg) ivgtt on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone100mg/m² po on day1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone100mg/m² po on day1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m² ivgtt on day 1
Study: NCT04572776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
Study: NCT03783377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-APOC3
Description: single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline (0.9% NaCl)
Description: calculated volume to match active treatment
Study: NCT03202290

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and clinical assessment
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and clinical assessment
Description: The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
Study: NCT03762577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground-based walking training
Description: Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
Study: NCT04265222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hipcheck Software
Description: Software

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Fluoroscopy
Description: Conventional Fluoroscopy
Study: NCT04147247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion
Study: NCT03362177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04147247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905681
Description: Infusion
Study: NCT05409950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement using socket shield technique
Description: Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
Study: NCT03592836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics
Description: intravenous administration of diuretics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics
Description: intravenous administration of diuretics
Study: NCT03407001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo non-contrast US
Study: NCT00789607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal APT Device or Transperineal Device will be used
Description: Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS probe
Description: Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
Study: NCT00206427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016
Description: Lapatinib, 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 500 mg PO
Study: NCT04513717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03877146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled Breathing Intervention
Description: Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
Study: NCT03872843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5milligram-325milligram Tablet
Description: Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
Description: Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
Study: NCT04344652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoscreening -
Description: external picture taken with a an phone based app
Study: NCT04513717

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Gonadotropin-releasing hormone (GnRH) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Gonadotropin-releasing hormone (GnRH) agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Gonadotropin-releasing hormone (GnRH) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Gonadotropin-releasing hormone (GnRH) agonist
Study: NCT04097769

Intervention type: DRUG
Group type: OTHER
Intervention: HX009
Description: During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
Study: NCT04964336

Intervention type: OTHER
Intervention: Analysis of B cells
Description: B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
Study: NCT04255433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study: NCT04469270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis
Description: Intramuscular injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections
Study: NCT02025543

Intervention type: DEVICE
Intervention: MRI
Description: R2 MRI scan

Intervention type: DEVICE
Intervention: MRI
Description: R2 MRI scan
Study: NCT04009499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT02824224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tamoxifen)
Description: Sugar pill manufactured to mimic the tamoxifen 10mg tablet
Study: NCT02403583

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention- Home Visits
Description: If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
Study: NCT01610856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: 4 Litres of polyethylene glycol bowel preparation solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: Polyethylene glycol 4L given in two split doses of 2L each
Study: NCT04366154

Intervention type: OTHER
Intervention: Questionnaire
Description: delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint

Intervention type: OTHER
Intervention: Questionnaire
Description: delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
Study: NCT00856999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
Study: NCT02388828

Intervention type: BIOLOGICAL
Intervention: lentiviral-based CART meso therapy
Study: NCT03350490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02104245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dispersion for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02454348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
Study: NCT04330417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Hand Training
Description: Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hand Therapy
Description: Stretching, Strengthening, Hand Functional Training